Cargando…
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
This open-label, single-center, Phase 3 study (NCT03546842) assessed the immunogenicity and safety of the nine-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine in Vietnamese males and females, with the aim to support 9vHPV vaccine licensure in Vietnam. Participants aged 9–26...
Autores principales: | Thiem, Vu Dinh, Quang, Nguyen Dang, Tuan, Nguyen Hai, Cheon, Kyeongmi, Gallagher, Nancy, Luxembourg, Alain, Group, Thomas, Badshah, Cyrus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189095/ https://www.ncbi.nlm.nih.gov/pubmed/33844623 http://dx.doi.org/10.1080/21645515.2020.1865739 |
Ejemplares similares
-
Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
por: Nolan, Katrina M., et al.
Publicado: (2023) -
Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022) -
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
por: Kjaer, Susanne K., et al.
Publicado: (2020) -
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
por: Olsson, Sven-Eric, et al.
Publicado: (2020) -
Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older
por: Thiem, Vu Dinh, et al.
Publicado: (2020)